Prospective comparison of FDG-PET and IBZM-SPECT in the differential diagnosis of parkinsonism

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003613

Enrollment

100

Registered

2012-03-12

Start date

2010-07-05

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G20 G23.1 G31.0 G20.0 G31.88

Interventions

Group 1: Patients with clinically suspected atypical parkinsonian syndromes (based on clinical symptoms and poor response to levodopa) receive IBZM-SPECT. All patients were clinically followed up for

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: suspected, but not yet verified early-stage atypical parkinsonian syndrome based on clinical symptoms and poor response to levodopa; Karnofsky score =40%)

Exclusion criteria

Exclusion criteria: relevant impairment or significant reduction of life expectancy caused by another disease

Design outcomes

Primary

Measure	Time frame
diagnostic accuracy of IBZM-SPECT and FDG-PET to differentiate between atypical parkinsonian syndromes and Lewy body diseases (Parkinson´s disease, Parkinson´s disease with dementia, Dementia with Lewy bodies) given as area under the receiver operating characteristics	—

Secondary

Measure	Time frame
diagnostic accuracy of FDG-PET to differentiate between subgroups of atypical parkinsonian disorders (progressive supanuclear palsy, corticobasal degeneration, multiple system atrophy), diagnostic measures are sensitivity, specificity, negative predictive value, positive predictive value	—

Countries

Germany

Contacts

Public ContactPhilipp T. Meyer

Abteilung für Nuklearmedizin

philipp.meyer@uniklinik-freiburg.de076127039990

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026